Sanofi Stock News

French drugmaker Sanofi said it would aim to further increase its earnings per share (EPS) this year as it reported rising fourth-quarter results on Friday.

Sanofi <> is estimated to announce Q4 earnings results on Friday, February 4, 2022, before the market opens.The consensus EPS estimate is €1.36 and Revenue estimate is €10.11B.In…

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. About 3 new molecular entities, or NMEs, were approved during the month, including Immunocore Holdings plc''s (NASDAQ: IMCR ) Kimmtrak for certain patients with advanced eye melanoma and Pfizer, Inc.''s (NYSE: PFE ) atopic dermatitis treatment Cibinqo. NME approval is an important indicator to measure innovation in drug research. NME approvals totaled 50 in 2021, almost equaling the numbers of the previous year. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN )- Sanofi (NASDAQ: SNY ), however, failed to get the nod for expanding the Libtayo label to include cervical cancer. Pfizer also faced rejection for its pediatric growth hormone deficiency treatment Somatrogon. A PDUFA date is the date/period by which the Food and Drug Administration is required to announce its verdict on a sponsor company''s regulatory application. This will determine the fate of millions of dollars invested in developing the treatment from the preclinical-stage to clinical testing.

Key Events This Week: ECB, BOE, Payrolls, Euro CPI And Earnings Galore It''s a relatively busy week with several key central bank announcements, notably from the ECB and BOE, as well as European CPI updates and the US payrolls report on Friday. Starting with the ECB, Deutsche Bank economists now expect a policy rate liftoff in December 2022 of 25bps, a view apparently shared by the market this morning. Theyre also anticipating a faster pace of tightening, with 25bp hikes in the deposit rate per quarter from December 2022, until rates reach +0.5% in September 2023. In terms of what it means for this February meeting, they write in their preview that they expect the slow, step-by-step pivot to exit will continue. Their view is that President Lagarde will reiterate the ECBs capacity to act once the inflation criteria in the rates guidance are met, whilst at the same time differentiating the needs of the Euro Area from the US. The other central bank decision that day is from the Bank of England, where expectations are for the BoE to follow up their December rate hike with another 25bps increase, taking the Bank Rate to 0.5%.

US Futures Start The Week With More Wild Swing In Another Volatile, Illiquid Session After a rollercoaster week that ended just barely higher following a late meltup on Friday, overnight volatile US stock futures swung to start the week, with Nasdaq 100 futures leading gains after rallying on Friday, before turning red and threatening to fizzle a global equity rally amid persistent worries over the Federal Reserve’s plan to hike interest rates this year. Emini S&P futures were down 0.5% or 21 points to 4401, after rising as high as 4437 and dropping as low as 4395 in another extremely illiquid session where China being offline for the week due to Lunar New Year did not help; Nasdaq futures were down 0.1% while Dow futures were lower 0.7%. Technology stocks led gains on the Stoxx Europe 600. Meanwhile, the dollar fell and oil rallied. As investors reconcile to a hawkish U.S. central bank coupled with strong earnings, the expensive parts of the U.S. stock market are undergoing a valuation re-rating along with the bond markets.

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announce that the EMA''s Committee for Medicinal Products for Human Use ((CHMP)) has adopted a positive opinion, recommending to extend

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use of Dupixent (dupilumab). [ALERT] Nic Chahine share

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announce the voluntary withdrawal of the supplemental Biologics License Application (sBLA) for Libtayo (cemiplimab-rwlc) as a

Regeneron Pharmaceuticals Inc  REGN and its partner Sanofi SA SNY have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical canc

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.57% were down 0.1% in premarket trading on Friday after the company and Sanofi SNY, +3.00% said they will no longer seek Food and Drug Administration

PALM BEACH, Fla. , Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.

Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.

The U.S. Food and Drug Administration ((FDA)) accepted to review Regeneron Pharmaceuticals <> and Sanofi''s <> application seeking approval of Libtayo (cemiplimab-rwlc)…